|
Market Closed -
NYSE
16:00:03 2026-10-26 EDT
|
5-day change | 1st Jan Change | ||
| 20.43 USD | +0.94% |
|
+4.18% | +31.05% |
| 10-25 | Takeda Pharmaceutical Eyes 2027 Japan Filing for Gastric Cancer Treatment | MT |
| 10-25 | Takeda to seek Japan approval for gastric cancer drug next year | RE |
Chart calendar Takeda Pharmaceutical Company Limited
Upcoming events on Takeda Pharmaceutical Company Limited
| 2026-10-29 | Earnings presentation | 06:00 |
| 2026-10-29 | Earnings release - Q2 2027 | 02:30 |
| 2027-01-27 | Earnings release - Q3 2027 |
Past events on Takeda Pharmaceutical Company Limited
| 2026-07-30 | Earnings release - Q1 2027 | |
| 2026-07-30 | Earnings presentation | 06:00 |
| 2026-06-23 | Board of Directors Meeting | |
| 2026-06-23 | Annual General Meeting | 21:00 |
| 2026-06-23 | Présentation aux Actionnaires / Analystes | 21:00 |
| 2026-05-13 | Earnings release - Q4 2026 | |
| 2026-05-13 | Earnings presentation | 06:00 |
| 2026-05-12 | Board of Directors Meeting | |
| 2026-03-28 | Information meeting | 20:30 |
| 2026-01-29 | Earnings release - Q3 2026 | |
| 2026-01-29 | Earnings presentation | 05:30 |
| 2025-10-30 | Earnings release - Q2 2026 | |
| 2025-10-30 | Earnings presentation | 06:00 |
Past dividends on Takeda Pharmaceutical Company Limited
| 2026-09-29 | Ex-dividend date - 102 JPY | 00:00 |
| 2026-03-30 | Ex-dividend date - 100 JPY | 00:00 |
Annual results
| Fiscal Period | March | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|
|
Net sales Million JPY | Released Forecast Spread | 4 263 762 4 099 295 4.01% | 4 581 600 4 611 639 -0.65% | 4 505 700 4 531 370 -0.57% | 4 701 837 | 4 795 879 | 4 925 220 |
|
EBITDA Million JPY | Released Forecast Spread | 942 077 1 044 660 -9.82% | 1 103 982 1 220 359 -9.54% | 1 129 888 1 227 941 -7.99% | 1 283 280 | 1 384 870 | 1 445 085 |
|
EBIT Million JPY | Released Forecast Spread | 214 100 264 737 -19.13% | 342 600 360 416 -4.94% | 408 800 433 006 -5.59% | 469 869 | 603 713 | 699 373 |
|
Earnings before Tax (EBT) Million JPY | Released Forecast Spread | 52 791 132 641 -60.2% | 175 084 179 480 -2.45% | 260 189 271 238 -4.07% | 298 897 | 455 587 | 549 333 |
|
Net income Million JPY | Released Forecast Spread | 144 067 134 022 7.5% | 107 900 134 894 -20.01% | 191 800 174 472 9.93% | 196 331 | 323 029 | 384 410 |
|
EPS JPY | Released Forecast Spread | 92,1 88,1 4.49% | 68,4 84,3 -18.9% | 122 112 8.57% | 126 | 199 | 244 |
| Announcement Date | 09/05/24 | 08/05/25 | 13/05/26 | - |
Quarterly results
| Fiscal Period | June | 2025 S1 | 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | 2026 S1 | 2026 Q3 | 2026 Q4 | 2027 Q1 | 2027 Q2 | 2027 S1 | 2027 Q3 | 2027 Q4 | 2028 Q1 | 2028 S1 | 2029 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million JPY | Released Forecast Spread | 2 384 000 2 243 050 6.28% | 1 144 200 1 132 186 1.06% | 1 053 400 1 074 356 -1.95% | 1 106 700 1 161 142 -4.69% | 1 112 815 1 184 529 -6.05% | 2 219 500 2 300 550 -3.52% | 1 191 700 1 193 271 -0.13% | 1 094 521 1 117 517 -2.06% | 1 219 900 1 149 550 6.12% | 1 155 786 | 2 307 000 | 1 233 440 | 1 129 380 | 1 159 000 | 2 327 000 | 1 157 000 |
|
EBITDA Million JPY | Released Forecast Spread | 366 200 354 850 3.2% | 253 977 340 250 -25.36% | 359 500 384 050 -6.39% | 150 249 223 350 -32.73% | 364 400 373 150 -2.34% | 363 950 | 402 150 | 218 350 | ||||||||
|
EBIT Million JPY | Released Forecast Spread | 350 600 179 750 95.05% | 66 900 33 500 99.7% | -74 900 -62 436 -19.96% | 184 600 150 566 22.6% | 69 034 125 591 -45.03% | 253 600 358 050 -29.17% | 168 800 165 025 2.29% | -13 582 4 315 -414.8% | 201 417 156 033 29.09% | 135 677 | 274 000 | 132 900 | 8 156 | 185 000 | 355 000 | 192 000 |
|
Earnings before Tax (EBT) Million JPY | Released Forecast Spread | 255 976 103 300 147.8% | 26 407 -15 170 274.07% | -107 299 -95 773 -12.04% | 150 600 114 799 31.19% | 28 174 88 256 -68.08% | 178 804 254 450 -29.73% | 133 900 98 878 35.42% | -52 500 -21 302 -146.46% | 162 718 98 779 64.73% | 40 553 | 155 750 | 108 629 | -13 133 | 145 000 | 275 000 | 152 000 |
|
Net income Million JPY | Released Forecast Spread | 187 300 87 850 113.2% | 23 800 -3 320 816.87% | -103 200 -77 118 -33.82% | 124 200 87 753 41.53% | -11 843 64 455 -118.37% | 112 400 188 950 -40.51% | 103 600 71 132 45.64% | -24 281 -18 003 -34.87% | 113 197 67 738 67.11% | 17 880 | 102 600 | 82 444 | 2 200 | 108 400 | 205 900 | 115 900 |
|
EPS JPY | Released Forecast Spread | 119 61,5 93.25% | 14,9 26,2 -43.28% | -65,4 -55,2 -18.3% | 79,4 49,6 60.22% | -7,83 33,8 -123.17% | 71,6 118 -39.55% | 65,7 43,1 52.39% | -15,3 -24,0 36.25% | 71,7 54,4 31.76% | 45,4 | 80,9 | 44,2 | -17,0 | 68,6 | 130 | 73,3 |
| Announcement Date | 31/10/24 | 30/01/25 | 08/05/25 | 30/07/25 | 30/10/25 | 30/10/25 | 29/01/26 | 13/05/26 | 30/07/26 | - | - | - | - | - | - | - |
| Today |  | Earnings release - Q3 2026 | |
| 2026-10-27 | | Board of Directors Meeting | |
| Today | | Earnings release - Q3 2026 | |
| 2026-10-27 | | Earnings presentation | |
| 2026-10-27 | | Earnings presentation | 21:00 |
| 2026-10-27 | | Board of Directors Meeting | 21:30 |
| 2026-10-27 | | Board of Directors Meeting | |
| 2026-10-28 | | Earnings release - Q3 2026 | 03:00 |
| 2026-10-28 | | Earnings presentation | 08:00 |
| 2026-10-28 | | Sales and Revenue Release - Q3 2026 | P |
Past sector events for Takeda Pharmaceutical Company Limited
| Today | | Earnings release - Q3 2026 | 04:00 |
| Today | | Earnings presentation | 05:00 |
| Today | | Earnings release - Q3 2026 | |
| Today | | Présentation aux Actionnaires / Analystes | 07:45 |
| Today | | Earnings release - Q3 2026 | |
| Today | | Earnings presentation | 03:30 |
| Today | | Earnings release - Q3 2026 | |
| Today | | Earnings release - Q2 2027 | |
| Today | | Earnings release - Q3 2026 | |
| Today | | Earnings release - Q3 2026 |
Quarterly revenue - Rate of surprise
Net sales - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Stocks
- 4502 Stock
- TAK Stock
- Calendar Takeda Pharmaceutical Company Limited
Select your edition
All financial news and data tailored to specific country editions
